← Aardvark Therapeutics, Inc. (AARD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Aardvark Therapeutics, Inc. (AARD)
Pharmaceutical Preparations · market cap $121M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Aardvark Therapeutics (AARD) is a small-cap pharmaceutical company with 33 employees and a $130M market cap, focused on its lead asset ARD-101 in Phase 3 for hyperphagia and a Phase 2 asset ARD-501 in autism spectrum disorder. The company holds $62.4M in cash but carries only ~9.9 months of runway against a $49M annualized R&D burn, creating a near-term financing imperative. No revenue has been generated to date.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ARD-101 | Phase 3 | Hyperphagia |
| Low Dose ARD-501 | Phase 2 | Autism Spectrum Disorder |
Price & technical context
3-month
-7.5%
6-month
+28.9%
12-month
-60.3%
52-wk range
$3.48–$17.41
vs 50-day MA
-13.9%
vs 200-day MA
-28.9%
Realized vol
138.3%
Max drawdown
-80.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AARD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.